Growth factor inhibitor

ArCOOH Morpholine EDC Growth factor-/ inhibitor 73 2006JME2210... 

Lucentis contains ranibizumab and is available for intravitreal injection. It is a vascular endothelial growth factor inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration. Unlike verteporfin, which is used in photodynamic treatment of age-related macular degeneration, ranibizumab does not require activation by local irradiation using non-thermal red light. 

Uses Neovascular wet macular degenoation Action Vascular endothelial growth factor inhibitor Dose 0.5 mg intravitreal inj qmo Caution [C ] Hx thromboembohsm Contra Periocular Infxn Disp Inj SE Endophthalmitis, retinal detachment/hemorrhage, cataract, intraocular inflammation, conjunctival hemorrhage, eye pain, floaters EMS None OD Unlikely, but immediate effect would be vision loss and pain d/t t ocular pressure... 

The enantioselective total synthesis of the epidermal growth factor inhibitor (-)-reveromycin B was completed by M.A. Rizzacasa and co-workers/° The key step to assemble the 6,6-spiroketal moiety was the HDA reaction between an a,P-unsaturated aldehyde (butylacrolein) and an enantiopure methylene pyran. The desired 6,6-spiroketal was obtained as a single enantiomer after heating the neat reactants in the absence of solvents at 110 °C for 2 days. 

Other areas of research include the development of drugs that block the capacity of oncogenes to turn cells malignant antagonists of growth factors inhibitors of cell cycle control factors and gene therapy to restore tumour suppressor gene function. 

A fundamental process in biology is the proliferation of cells mediated by the cell cycle. On the basis of previous studies, Kuo et al. identified the pyrazino-pytidine compound 360 as a potent vascular endothelial growth factor inhibitor and the pyrimidino-pyridine species 361 as a moderately potent cyclin-dependent kinase (CDK) inhibitor (Figure 36). A proposed combination of CGP-60474 and compound 361 led to the discovery of the [l,3,5]triazino-pyridines 362 as a new series of potent CDK inhibitors <2005JME4535>. 

In the example record QUI339 (Figure 4.3), the aminoquinazoline fragment of a prototypical angiogenic growth factor inhibitor was replaced by the analogous amidine of anthranilic add and the attachment via the amino ( NH ) group is specified. 

Small HY, Montezano AC, Rios FJ et al (2014) Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors understanding and managing a new syndrome. Can J Cardiol 30 534-543... 

Faruque LI, Lin M, Battistella M et al (2014) Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS... 

PanGenetics Limited is investigating another nerve growth factor inhibitor. The investigational agent known as PGllO is being studied for the treatment of osteoarthritis pain. 

Potential adverse events remain unknown, but, like Tanezumab, this nerve growth factor inhibitor may be linked to abnormal peripheral sensation, neuropathy, and hyperesthesia. PGllO is also administered intravenously. 

Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev December 2012 88(12) 937-41. http //dx.doi.Org/10.1016/j.earlhumdev.2012.09.019. Epub 2012 October 15. PubMed PMID 23078830. 

Campbell RJ, GiU SS, BronskiU SE, Paterson JM, Whitehead M, Bell CM. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors nested case-control study. BMJ July 4, 2012 345 e4203. http //dx.doi.org/10.1136/bmj.e4203. PubMed PMID 22763393 PubMed Central PMOD PMC3389519. 

---